Key facts
- This page summarizes Camille D. Samuels's Form 4 filing for Unity Biotechnology, Inc. (UBX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2024, 16:30.
Camille D. Samuels - 21 Jun 2024 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)
- Reporting relationship
- Director
- Issuer ticker
- UBX
- Reported as of
- 21 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2024, 16:30:19 UTC
- Prior SEC filing
- 26 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexander Nguyen, Attorney-in-Fact for Camille D. Samuels
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Camille D. Samuels filed Form 4 for Unity Biotechnology, Inc. (UBX) on 21 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
UBX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 21 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $1.38
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
Footnote F2
The reporting person is a member of VR Management, LLC (the "Management Company"). Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the reporting person may be deemed the indirect beneficial owner of the reported shares underlying the option through her interest in the Management Company. The reporting person disclaims beneficial ownership of the reported shares except to the extent of her pecuniary interest therein.